Published on
Apr 7, 2025
Dr Zhang on the Rationale of Evaluating SIM0270/Everolimus in ER+/HER2– Advanced Breast Cancer
“After CDK4/6 inhibitors, we have a lot of options, such as mTOR inhibitors, [antibody-drug conjugates], and PARP inhibitors. However, everolimus has an indication in China, but some inhibitors, especially PIK3CA inhibitors, were not approved by our …
Source:
OncLive
-
Label Pending
